PR-inside.com
DeutschEnglish
Mit unserem RSS-Feed sind Sie immer auf dem neusten Stand
rss feed


Mehr Informationen
Wirtschaft & Industrie

FDA Clears Apira Science's iGrow(R) Hair Growth Platform The iGrow Platform Is the First Hands-Free Home Use Low Level Laser Therapy Hair Growth System Cleared by the FDA


© Marketwire 2013

(PR-inside.com 15.01.2013 14:37:16)

Drucken Ausdrucken

 

 

BOCA RATON, FL -- (Marketwire) -- 01/15/13 -- Apira Science, Inc. ( www.igrow2laser.com : ), a global leader in aesthetic light-based therapies, today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its iGrow® Hair Growth Platform. This patented red light technology device is now FDA cleared for the treatment of androgenetic alopecia (male pattern hair loss). This system treats affected areas of the scalp, requires no manual movement, and is the first hands-free Low Level Laser Therapy (LLLT) hair growth device cleared by the FDA for use at home.





"This landmark achievement represents a significant and strategic milestone for Apira Science. The iGrow platform provides effective LLLT treatment that was previously only available in a professional setting. This safe and effective treatment for androgenetic alopecia offers significant advantages over other LLLT devices currently on the market, and will forever change the way men's hair loss is treated," said Nicholas Brox, president and CEO, Apira Science, Inc. "We have invested in innovative engineering and applied science to develop an effective light-based hair growth system that consumers can use in the privacy of their homes."



Low-level laser hair growth therapy is rapidly becoming widely accepted as an alternative to drugs and surgery. Male pattern hair loss affects a large portion of the male population according to The International Society of Hair Restoration Surgery. They estimate that that over 35 million men in the US are afflicted with this condition. The onset of male pattern hair loss can begin in the late teen years and progress over a lifetime.



Products that address the in-home device market for LLLT hair growth are expected to grow exponentially through the continued introduction of effective and convenient treatments.



"The iGrow platform utilizes non-invasive, low-level red laser and LED light to effectively re-energize the unhealthy cells that are in and around the hair follicle," said Jeff Braile, president, medical device division, Apira Science, Inc. "We designed this platform to optimize all that is scientifically known about LLLT for hair growth. The results from our recently completed study unequivocally proved the effectiveness of the iGrow's low-level laser therapy in the treatment of androgenetic alopecia."



Apira Science, Inc. has leveraged years of scientific research, knowledge and expertise in the practical application of low-level light therapy. This dedication and experience has led to the development and manufacture of the iGrow Hair Growth Platform.



Additional information is available at: www.igrow2laser.com :



About Apira Science, Inc.
Apira Science, Inc. is an established leader and has been a pioneer in Low Level Light Therapy (LLLT) for over a decade. The iGrow Hair Growth Platform is the result of Apira Science, Inc.'s experience, scientific innovation and knowledge of the application of LLLT. This patented home use system is easy to use and provides an effective hair growth treatment for men with male pattern hair loss (androgenetic alopecia).



iGrow is a registered trademark of Apira Science, Inc.




Press contact:
Jeff Braile
President, Medical Products Division
(800) 651-4202
Outside the US: +1 (561) 252-1229
Email Contact : docid: 13973588.nitf -->

Presse-Information:




Kontakt-Person:



Erklärung: (C) Das Copyright für sämtliche Pressemeldungen und Bilder, die mit Marketwire gekennzeichnet sind und auf PR-inside.com publiziert werden, obliegt der Agentur Marketwire. Dieser Artikel darf ohne schriftliche Genehmigung der Agentur Marketwire weder kopiert noch veröffentlicht werden. Wenn Sie Fragen zu den veröffentlichten Meldungen haben, kontaktieren Sie bitte Marketwire unter der Internetadresse (http://www.marketwire.com/).
Aktuelle Nachrichten
Lesen Sie die aktuellsten Nachrichten
www.newsenvoy.com


AGB | Datenschutz | Impressum | Kontakt